These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 16402903)

  • 1. The proteasome and proteasome inhibitors in cancer therapy.
    Voorhees PM; Orlowski RZ
    Annu Rev Pharmacol Toxicol; 2006; 46():189-213. PubMed ID: 16402903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ubiquitin proteasome pathway from bench to bedside.
    Orlowski RZ
    Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
    Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
    Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathways: targeting proteasomal protein degradation in cancer.
    Molineaux SM
    Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib and its role in the management of patients with multiple myeloma.
    Orlowski RZ
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Cheriyath V; Jacobs BS; Hussein MA
    Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
    Dick LR; Fleming PE
    Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
    Satou Y; Matsuoka M
    Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An historic perspective of proteasome inhibition.
    Esseltine DL; Mulligan G
    Semin Hematol; 2012 Jul; 49(3):196-206. PubMed ID: 22726542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.
    Driscoll JJ; Chowdhury RD
    Cancer Lett; 2012 Dec; 325(2):147-54. PubMed ID: 22781397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Proteasome inhibitors].
    Saeki Y; Fukunaga K; Tanaka K
    Nihon Rinsho; 2010 Oct; 68(10):1818-22. PubMed ID: 20954323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.